Table 3 Cellular therapies and clinical trials for BTKi-resistant MCL
CAR therapy (Company) | Trial Name | Target | Study (N) | Outcomes | Adverse events | CT identifier (Ref) |
|---|---|---|---|---|---|---|
Brexucabtagene autoleucel; KTE-X19 (Kite Pharma) | ZUMA-2 | CD19 | R/R MCL Phase 2 (74) | ORR 91% CR 68% | CRS 15%, cytopenias 94%, infection 36% | |
Brexucabtagene autoleucel; KTE-X19 (Kite Pharma) | US Lymphoma CAR T Consortium | CD19 | R/R MCL Phase 2 (93) | ORR 86% CR 64% | CRS 88% ICANS 58% | NCT02601313 [172] |
Lisocabtagene maraleucel; JCAR017 (Juno Therapeutics) | TRANSCEND NHL001 | CD19 | R/R MCL Phase 2 (32) | ORR 84% CR 59% | CRS 50% ICANS 28% | NCT02631044 [174] |
Tisagenlecleucel (Novartis) | TARMAC | CD19 | R/R MCL Phase 2 (20) | ORR 90% CR 80% | CRS 73% | NCT04234061 [180] |
CD19 CAR T cells (Wuhan Union Hospital, China) | – | CD19 | R/R MCL Phase 3 (24) | Recruiting | Recruiting | NCT05020392 |
CD19 CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes (City of Hope Medical Center) | – | CD19 | R/R MCL Phase 2 (36) | Recruiting | Recruiting | NCT04484012 |
WZTL-002 (Malaghan Institute of Medical Research) | ENABLE | CD19 with TLR2 | MCL and other B-NHL Phase 1 (30) | Recruiting | Recruiting | NCT04049513 [177] |
BAFFR-targeting CAR T (PeproMene Bio, Inc.) | – | BAFFR | MCL and other B-NHL Phase 1 (18) | Recruiting | Recruiting | NCT05370430 |
SYNCAR-001 (Synthekine) | – | CD19, co-expressing IL-2 beta receptor | MCL and other B-NHL Phase 1 (36) | Recruiting | Recruiting | NCT05665062 |
PRGN-3007 UltraCAR-T (Precigen, Inc Moffitt Cancer Center) | – | ROR-1 | MCL and other B-NHL Phase 1/1b (88) | Recruiting | Recruiting | NCT05694364 [178] |
RD14-01 (He Huang) | – | ROR-1 | MCL and other B-NHL Phase 1 (18) | Recruiting | Recruiting | NCT05444322 |
LV20.19 (Medical College of Wisconsin) | – | CD19/20 | Phase 1 (10) | ORR 100% CD 60% | Grade 1–2 CRS 10% | NCT03019055 [181] |
MB-106 (Mustang Bio) | – | CD20 | R/R MCL Phase 1 (3) | PR | No CRS or ICANS ≥ Grade 3 | NCT03277729 NCT05360238 |
NKX019 (Nkarta Inc) | – | CD19 | MCL and other B-NHL Phase 1 (150) | Recruiting | Recruiting | NCT05020678 |